Dyne Therapeutics, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Dyne is a clinical-stage biotechnology company developing muscle-disease therapeutics using its FORCE platform. It has no approved products and reported no revenue.
Financial results and position
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $44.5 million | $37.5 million |
| General and administrative expense | $24.6 million | $7.9 million |
| Total operating expenses | $69.2 million | $45.5 million |
| Net loss | $65.6 million | $44.2 million |
| Basic and diluted net loss per share | $0.81 | $0.78 |
| Operating cash used | $78.5 million | $46.9 million |
- At March 31, cash and cash equivalents were $272.0 million and marketable securities were $181.5 million, totaling $453.5 million. Dyne said these resources were expected to fund operating expenses and capital needs through 2025; this estimate depends on assumptions that may change.
- Current assets were $488.1 million and current liabilities were $22.4 million. Total liabilities were $44.2 million, including lease liabilities; the balance sheet reported no borrowings.
- Financing provided $408.4 million of cash, principally from a January follow-on offering ($323.9 million net) and ATM sales. The quarter’s ATM sales generated $97.9 million net, of which $24.3 million was unsettled at quarter-end and received in April.
- Investing activities used $179.8 million, primarily reflecting purchases of marketable securities. No revenue or profit margins are available to assess because the company has not generated revenue.
Changes versus the prior comparable period
- Net loss increased by $21.5 million year over year. R&D expense rose $7.0 million, driven by DYNE-251 manufacturing and trial activity, preclinical research, and increased personnel and facility costs.
- G&A expense increased $16.7 million. Stock-based compensation accounted for much of the increase, including $13.7 million recognized after acceleration and modification of the former CEO’s options and restricted stock units under separation and consulting agreements.
- Operating cash use increased $31.6 million, partly due to a $28.8 million decrease in accounts payable and other liabilities. Cash and marketable securities rose substantially following equity financing.
- Shares issued and outstanding increased from 61.5 million at December 31, 2023 to 87.1 million at March 31, 2024, reflecting the public and ATM offerings and equity awards.
Outlook, programs and risks
- DYNE-101 (DM1): The Phase 1/2 ACHIEVE trial had enrolled 56 patients through the 6.8 mg/kg Q8W cohort. Dyne aimed to start registrational cohorts by year-end 2024 and expected higher-dose cohort data in the second half of 2024.
- DYNE-251 (DMD): The Phase 1/2 DELIVER trial had enrolled 48 patients through the 40 mg/kg Q8W cohort. Dyne likewise targeted registrational cohorts by year-end 2024 and expected higher-dose data in the second half of 2024. DYNE-251 has FDA Fast Track and orphan-drug designations.
- Dyne described initial clinical findings for both programs as positive and reported favorable safety profiles in the assessed cohorts. The company cautioned that early-stage results may not predict later trial outcomes; its comparison of DYNE-251 with eteplirsen was cross-trial, not head-to-head.
- The FSHD program remains under evaluation; Dyne planned an update in 2024. The previously deferred DYNE-301 IND submission had not been reinstated in the filing.
- Management expects significant ongoing losses and rising expenses as development advances. Continued operations will require substantial funding; future equity financing could dilute shareholders, while debt or collaborations could impose restrictions or require licensing rights.
- Key risks include clinical and regulatory failure or delay, uncertain translation of early data, patient-enrollment challenges, reliance on third-party manufacturers and CROs, single-source supply dependencies, competition, and intellectual-property and financing risks.
- John Cox became President and CEO in March 2024, replacing Joshua Brumm. Management reported disclosure controls were effective and no material change in internal control over financial reporting during the quarter. The filing reported no legal proceedings.
Important facts for investors to verify
- Whether cash burn, trial spending and financing needs remain consistent with the stated runway through 2025.
- Timing and results of the expected H2 2024 higher-dose data and year-end 2024 registrational-cohort plans for ACHIEVE and DELIVER.
- How later, larger clinical datasets confirm efficacy and safety, including the relevance of cross-trial comparisons and observed liver-enzyme elevations in DYNE-101 participants.
- Further share issuance, ATM activity and equity-compensation effects on dilution; reconcile the $24.3 million quarter-end ATM receivable with April settlement.
- Progress on the FSHD program and any 2024 update, alongside manufacturing capacity and supplier continuity for clinical programs.